Published : 14 Nov 2024
Aagami, Inc. are pleased to announce that our US client has awarded a contract expansion extension to support them in JV/Acquisition/Investment initiatives.
The client is seeking Acquisition /JV for their extremely safe and effective Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial Ongoing in AU).
The asset has applicability for a host of other indications. Patents are granted in all 12 regions applied. Aagami are also representing the client at JPM week 2025 and Biotech Showcase 2025 in San Francisco.
The scope of the assignment has been expanded to include the following:
Nutraceuticals portfolio in the US Market or Global Market ready products for new Global Distributors.
· All the Nutraceutical products are potential patent-pending.
· In vitro and animal studies done with the peer-review papers published.
· All the products available with new additional distribution and selling interests from several parties in multiple regions (agreement(s) process in development).
· Several peer reviewed papers are published.
a. Greenselenium® (Bioavailable selenium)
i. In the US market as Dietary supplement
ii. Addresses Chronic inflammatory and degenerative conditions, Keshan Disease, Kashin-Beck Disease, Myxedematous Endemic thyroid goiter.
iii. Has high potential to be advanced as a Pharma drug
b. SlimTrym® (poly methoxy-flavones, green tea catechins, and lychee fruit)
i. Market ready as Dietary supplement
ii. Prevention and treatment of obesity
c. Turmericimmune™? (water extract of Curcuma longa (L.) [vern. Turmeric] roots)
i. In the US market as Dietary supplement
ii. Tissue repair, regeneration, and immunity
iii. Has high potential to be advanced as a Pharma drug
d. FB3® Fusion (Coleus forskohlii (Briq.), Salacia reticulata (Wight.), Sesamum indicum (L.)
i. Market ready as Dietary supplement
ii. For Health Weight Management
e. Kannan™ (Sceletium tortuosum)
i. Market ready as Dietary supplement
ii. Addresses Stress, Mood, Anxiety, Cognition, depression
iii. Stamina
f. Adaptrin®
i. In the US market as Dietary supplement
ii. Supports the healthy cardiovascular and immune systems
iii. Based on the long-standing tradition of nutritional use and published studies, Adaptrin lowers stress levels, sharpens memory, overall energy and alertness, sleep patterns; and promotes an increased general subjective sense of well-being.
iv. Has high potential to be advanced as a Pharma drug
g. Serenity-151™ (contains Adaptogens)
i. In the US market as Dietary supplement
ii. Anti-stress, anti-sleep disorders, improve blood microcirculation, tissue oxygenation, and nourishment
iii. Improves intellectual performance, emotional composure, and memory function
iv. Has high potential to be advanced as a Pharma drug
h. Vigor-149
i. In the US market as Dietary supplement
ii. Maintaining hormonal balance and libido in andropause or menopause and psychosomatic conditions caused by stress
iii. Mental exhaustion, giddiness, depression, and decreased physical performance associated with andropause and menopause.
iv. Has high potential to be advanced as a Pharma drug
Additionally, Client's proprietary Strip Melts® Technology (OTF Delivery System) for all products is available considering many people (incl. Seniors) find it difficult to take tablets and capsules. Client has lined up an FDA Approved Pharmaceutical Manufacturing Facility in the USA. That comes as an added potential benefit.
Developed by five generations of physicians, with over 150 years of practical experience and over 30 years of systematic scientific research.
More details on each product are available for review.
Distinguished Inventor
Client is seeking advanced seed funding (culminating to Series A) of up to US$25 million.
Strategic investors are offered:
If you would like to know more about this opportunity, please contact us.